ALXN - Alexion Pharmaceuticals, Inc.
128.93 0.00 (0.00%)
After hours: 5:27PM EST
| Previous Close | 129.42 |
| Open | 128.48 |
| Bid | 123.30 x 1000 |
| Ask | 128.90 x 800 |
| Day's Range | 128.05 - 129.78 |
| 52 Week Range | 92.56 - 140.77 |
| Volume | 1,169,679 |
| Avg. Volume | 1,765,898 |
| Market Cap | 28.812B |
| Beta (3Y Monthly) | 1.54 |
| PE Ratio (TTM) | 370.49 |
| EPS (TTM) | 0.35 |
| Earnings Date | Apr 24, 2019 - Apr 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 163.56 |
- Zacks•5 days ago
Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings
Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.
- Thomson Reuters StreetEvents•6 days ago
Edited Transcript of ALXN earnings conference call or presentation 4-Feb-19 1:00pm GMT
Q4 2018 Alexion Pharmaceuticals Inc Earnings Call
- Zacks•6 days ago
The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion
The Zacks Analyst Blog Highlights: Disney, Eli Lilly, U.S. Bancorp, Prudential and Alexion
- Zacks•7 days ago
Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp
Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp
- Business Wire•7 days ago
Alexion Announces Creation of New Roles on Executive Leadership Team
Alexion Pharmaceuticals, Inc. (ALXN) today announced the creation of new roles within its executive leadership team. Anne-Marie Law has been appointed to the newly created role of Chief Patient and Employee Experience Officer. Aradhana Sarin, M.D., has been appointed to the newly created role of Chief Strategy and Business Officer.
- Zacks•8 days ago
Is Alexion (ALXN) a Great Growth Stock?
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Alexion (ALXN).
- Markit•11 days ago
See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ALXN totaled $17.53 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•12 days ago
Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GuruFocus.com•13 days ago
Alexion Pharmaceuticals Inc (ALXN) Files 10-K for the Fiscal Year Ended on December 31, 2018
For the last quarter Alexion Pharmaceuticals Inc reported a revenue of $1.1 billion, compared with the revenue of $910.1 million during the same period a year ago. For the last five years Alexion Pharmaceuticals Inc had an average revenue growth rate of 20.3% a year. The Alexion Pharmaceuticals Inc enjoyed an operating margin of 38.6%, compared with the operating margin of 22.64% a year before.
- Investor's Business Daily•15 days ago
Biotech Reports Solid Fourth Quarter, But Slips On Mixed Guidance
Alexion Pharmaceuticals stock slipped Monday on a solid fourth quarter, as 2019 sales guidance came in slightly short. Alexion stock dipped in early trading, but is still consolidating.
Yahoo Finance•15 days agoStocks rise amid next batch of corporate earnings
Stocks were mixed as investors anticipated another busy week for corporate earnings and the release of a host of economic data, which had previously been delayed due to the month-long partial government shutdown.
Motley Fool•15 days agoAlexion Pharmaceuticals (ALXN) Q4 2018 Earnings Conference Call Transcript
ALXN earnings call for the period ending December 31, 2018.
- Zacks•15 days ago
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.
- CNBC•15 days ago
Stocks making the biggest moves midday: Papa John's, Sysco, Clorox & more
Papa John's PZZA — Shares of the embattled pizza maker rose nearly 9 percent after the company announced Starboard Value has taken a $200 million stake in the company . Starboard CEO Jeffrey Smith was also named the new Papa John's chairman. Maxwell Technologies MXWL — Tesla announced it was acquiring Maxwell Technologies for about $218 million , sending the energy technology company's stock up more than 49 percent.
- Zacks•15 days ago
Q4 Earnings Soldier on Gamely: GOOGL, CLX & More
Eearnings reports to this point, based on strong consumer confidence and historically robust employment data (see Friday's 300K+ new jobs created last month), have been surprisingly positive amid these various and unpredictable headwinds.
- Investor's Business Daily•15 days ago
Stocks Open Mixed, Dow Jones Drags Ahead Of Alphabet Earnings
Drug makers were active Monday, led by Alexion and Bristol-Myers Squibb, as stocks opened mixed and the Dow Jones industrials dug in to hold 25,000.
- Motley Fool•15 days ago
Here's Why Alexion Pharmaceuticals Gained 26.3% in January
Positive clinical trial results for the company's follow-up to Soliris gave investors a reason to cheer.
- Zacks•15 days ago
Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates
Alexion beat both earnings and sales estimates in the fourth quarter of 2018.
- CNBC•15 days ago
Stocks making the biggest moves premarket: Papa John's, Spotify, Clorox, Yelp & more
Papa John's Pizza PZZA – Activist investor Starboard Value has taken a $200 million stake in the pizza chain, and Starboard CEO Jeffrey Smith will be named chairman. Starboard said the investment follows the conclusion of a strategic review by the company that positions it for stronger growth. Alexion Pharmaceuticals ALXN – The drugmaker reported adjusted quarterly profit of $2.14 per share, beating the consensus estimate of $1.82 a share.
- Associated Press•15 days ago
Alexion: 4Q Earnings Snapshot
On a per-share basis, the Boston-based company said it had a loss of 20 cents. Earnings, adjusted for one-time gains and costs, came to $2.14 per share. The results beat Wall Street expectations. The average ...
- Investing.com•15 days ago
Evolus Rises Midday as Botox Drama Unfolds
Investing.com - Evolus was higher in midday trading after it received regulatory approval for a cheaper version of Botox, just days after rival Allergan (NYSE:AGN) claimed the company stole trade secrets.
- Business Wire•15 days ago
Alexion Reports Fourth Quarter and Full Year 2018 Results
BOSTON-- -- 4Q18 total revenues of $1,128.8 million, a 24 percent increase over 4Q17 and a 30 percent volume increase 4Q18 GAAP diluted EPS of $ ; non-GAAP diluted EPS of $2.14 2019 guidance: revenue $4,625 to $4,700 million; GAAP diluted EPS of $6.14 to $7.26; non-GAAP diluted EPS of $9.10 to $9.30 SOLIRIS ® for Generalized Myasthenia Gravis best Alexion launch in first year following regulatory approval ...
- Barrons.com•18 days ago
Why Amgen Should Buy Alexion Pharmaceuticals
Biotech giant Amgen may be on the prowl for an acquisition target, and Piper Jaffray’s Christopher Raymond thinks that Alexion Pharmaceuticals could be a good fit.
- Business Wire•18 days ago
Alexion to Highlight Rare Disease Portfolio at Investor Day
Alexion Pharmaceuticals today announced that the Company will host an Investor Day on Wednesday, March 20, from 8:00am to 12:30pm ET. Alexion’s leadership team will highlight the continued advancement of the Company’s highly innovative pipeline which is focused on serving patients with rare diseases.
